Patients with hematologic malignancies and hematopoietic stem cell transplant (HSCT) recipients are at high risk for bacterial bloodstream infections (BSI) owing to resistant organisms. Data describing the outcomes of vancomycin-resistant enterococcal (VRE) BSI in this patient population are limited. We performed a retrospective cohort study of all cases of VRE BSI that occured between February 1996 and December 2002 on the Leukemia/HSCT unit at Barnes-Jewish Hospital. There were 68 episodes of VRE BSI in 60 patients with acute (53%) or chronic (8%) leukemia, non-Hodgkin's lymphoma (22%) or other malignant hematologic disorders (17%). A total of 13, 32 and 32% were recipients of autologous, related and matched-unrelated transplants, respectively. Forty-two of allograft recipients had active acute graft-versus-host disease (GVHD) and 32% chronic GVHD. Only 57% were neutropenic, 52% had refractory/relapsed malignancy and 60% had end organ dysfunction with a median APACHE II score of 17. Median survival after VRE BSI was 19 days. Pneumonia, receipt of anti-fungal drugs and low APACHE II score at the time of the VRE BSI remained significant risk factors for death on multivariable analysis. Our analysis suggests that in patients with hematological malignancies or HSCT, VRE may not have the behavior of a virulent pathogen. VRE BSI may simply be a marker of these patients' already existing critical medical condition.
Introduction
Patients with hematologic malignancies and hematopoietic stem cell transplant (HSCT) recipients are at high risk for bloodstream infections (BSI) that arise from organisms that normally colonize the human intestine. [1] [2] [3] [4] Because of their high severity of underlying illness, prolonged hospitalization and frequent broad-spectrum antibiotic exposures, these patients are commonly colonized with resistant organisms and therefore at high risk for BSI owing to resistant organisms. 1, 2 This is important because infections owing to resistant organisms are associated with increased morbidity, costs and mortality. 5 Enterococci are normal inhabitants of the human colon and are the third most frequent cause of health-careassociated infections in the United States. [6] [7] [8] Up to 73% of enterococcal BSIs are due to vancomycin-resistant strains. 9 Risk factors for vancomycin-resistant enterococcal (VRE) colonization and infection include prolonged hospitalization, intensive care unit (ICU) stay, advanced age, immunocompromised state, neutropenia, high severity of underlying illness, antibiotic exposure, and indwelling urinary and vascular catheters, 8, [10] [11] [12] [13] characteristics commonly found in patients on HSCT units. Several studies have investigated the significance of VRE infections in different patient populations and controversy exists as to whether VRE infections are associated with worse outcomes compared to vancomycin-sensitive enterococci. [14] [15] [16] [17] [18] [19] [20] [21] Although some studies have indicated VRE infections are associated with worse outcomes in immunocompromised patients, 19 ,20 data on VRE infections in patients with hematologic malignancies and HSCT recipients are limited. 21, 22 Therefore we conducted a retrospective cohort study to determine the patient characteristics associated with VRE BSI and risk factors for death in these patients.
Patients and methods

Study design
All cases of VRE BSI occurring between February 1996 and December 2002 on the HSCT unit at Barnes-Jewish Hospital were prospectively identified by the Infection Control Department. Barnes-Jewish Hospital is a 1251-bed tertiary care facility located in St Louis, MO and is affiliated with Washington University School of Medicine. The HSCT unit has 27 positive pressure, high efficiency particulate air-filtered, single-occupancy rooms and can accommodate up to six patients requiring ICU care. All patients with acute leukemia and HSCT recipients are admitted to this unit. Nine hundred and sixty-eight autologous and 612 allogeneic transplants were performed during the study period. Although there was no active screening for enteric VRE colonization during the study period, VRE screening was carried out on all stools sent for Clostridium difficile testing. The standard antibiotic regimens for neutropenic fever during the study period consisted of cefepime monotherapy (ceftazidime from February 1996 to January 1998) for leukemics, autologous, and sibling allogeneic transplants recipients and imipenem plus vancomycin for unrelated donor allogeneic recipients. Washington University School of Medicine Human Studies Committee approval was obtained for this study.
Chart review was conducted with a standardized data collection tool. Patient-related variables collected at the time of the VRE BSI included: age, underlying disease, stage of underlying disease, transplant history, Eastern Cooperative Oncology Group (ECOG) score on admission and at time of the VRE BSI, co-morbidities, graftversus-host disease (GVHD), immunosuppressant drugs, APACHE II score 48 h before and at the time of VRE BSI and discharge status. All inpatient antibiotics, chemotherapeutic agents and infections were collected if present within 42 days before the VRE BSI. Antibiotic exposures were aggregated by type of coverage (gram positive, gram negative, anaerobic and fungal) as described previously. 17, 23 Vancomycin exposure was also reported separately.
Study definitions
Episodes of VRE BSI were prospectively identified by the Infection Control Department at Barnes-Jewish Hospital. A VRE BSI was defined as X2 sets of blood cultures positive for VRE drawn within 24 h of each other or one set of blood cultures positive and the presence of fever (438.01C), chills or hypotension when cultures were drawn. Infections were considered secondary if the same organism was cultured from another site, other than stool, within the previous 48 h. Bloodstream infections were considered polymicrobial if more than one organism grew from the same set of blood cultures. VRE BSIs were considered recurrent if VRE was isolated from blood cultures after treatment with an appropriate dose and duration of an effective antibiotic(s) plus documentation of negative blood cultures or resolution of symptoms associated with the first BSI after the initiation of antibiotics.
Infections were defined by the National Nosocomial Infection Surveillance System (NNIS) definitions for nosocomial infections. 24 Infections were considered fungal if fungi grew from an otherwise sterile site or invasive disease was seen on histopathology. Cytomegalovirus (CMV) viremia was defined as persistently positive qualitative PCR or culture from the blood or a quantitative PCRX10 000 copies/ml. CMV pneumonia was defined as the presence of histopathological evidence of CMV pneumonia or a positive culture by bronchoalveolar lavage in a patient with radiographic evidence of pneumonia. GVHD was diagnosed and graded according to standard definitions. 25, 26 Mortality attributable to VRE BSI was defined as a patient who had an acute clinical deterioration temporally associated with the VRE BSI culminating in death.
Data analysis
Risk factors for death were analyzed by the Student's t-test or Mann-Whitney U-test for continuous variables and the w 2 test for categorical variables. Kaplan-Meier analysis was used to calculate median survival after VRE BSI. Backwards, stepwise Cox proportional hazards (Pp0.05 for entry, PX0.1 for exclusion) were used to determine risk factors for death at discharge on multivariable analysis. For measures of association, a two-tailed Pp0.05 was considered to be significant.
Results
Epidemiological characteristics of VRE colonization and BSI
During the 83-month-study period 334 patients screened positive for enteric VRE colonization. Sixty-eight episodes of VRE BSI were observed in 60 patients (for patients with 41 VRE BSI only data from the first VRE BSI are described from this point forward). The incidence of VRE BSI ranged between 0.6 and 0.9 VRE BSI/1000 patient days from 1996 to 1998 ( Figure 1 ). During this period it was hospital policy for all health-care workers to wear gowns and gloves before entering the room of patients colonized with VRE. In 1998 this policy was changed to gloves alone. This was followed by a sharp rise in the rate to 2.1 VRE BSI/1000 patient-days in 2001. As a result of this increase, gowns and gloves were reinstituted and the rate regressed back to 1.3 VRE BSI/1000 patient-days. 
Microbiological characteristics
Of the 334 patients who were known to be enterically colonized with VRE, 42 (13%) developed a VRE BSI. Therefore 70% (42/60) of those who developed VRE BSI were known to be enterically colonized with VRE when they developed their VRE BSI. Eight (13%) VRE BSI were polymicrobial BSIs. Other organisms isolated were coagulase-negative Staphylococcus (n ¼ 4), Pseudomonas aeruginosa (n ¼ 3), Acinetobacter calcoacetius (n ¼ 1) and Stenotrophomonas maltophilia (n ¼ 1). All VRE isolates were Enterococcus faecium except one isolate, which was Enterococcus feacalis. The median duration of VRE bacteremia was 1 day (range 1-9); 22 (37%) of patients had more than 1 day of VRE bacteremia. Fifty-five (92%) patients had primary VRE BSI. The secondary VRE BSI were attributed to the urinary tract (n ¼ 3) and intraabdominal infections (n ¼ 2).
Patient characteristics
The median age of VRE BSI patients was 46 years (range 20-75) ( Table 1) ; 57% were male and the median ECOG score on admission was 2 (range 1-4). The most common diagnosis was acute leukemia (53%), followed by lymphoma (22%) and chronic myelogenous leukemia (8%); 24 (40%) patients were in remission, and 31 (53%) had relapsed or refractory disease. At the time of the VRE BSI, 19 (32%) patients were recipients of matched unrelated donor transplants, 19 (32%) sibling matched transplants, eight (13%) autologous transplants and 14 (23%) had not been transplanted. Seventeen (45%; 17/38) allograft recipients were transplanted after a failed allograft and one (12%) after a failed autograft. The VRE BSI occurred a median 12 days after transplant (range À12 to 770) in allogeneic and 10.5 days (À5 to 77) in autologous recipients. At the time of the VRE BSI, 16 (42%) of the allograft recipients had acute GVHD at one or more sites (14 skin, seven gastrointestinal, five liver) and 12 (32%) had chronic GVHD (10 skin, six gastrointestinal, four liver and two mucosalivary).
Severity of underlying illness
Sixty-eight percent of patients with VRE BSI were previously hospitalized in the 30 days before the admission during which the VRE BSI occurred. The median length of stay before the VRE BSI was 17 days (range 0-77).
Infections were common in the 42 days preceding the VRE BSI (some patients had more than one infection). Twentyeight (47%) patients had a non-VRE bacterial BSI in the 42 days preceding the VRE BSI, 6 (10%) had C. difficileassociated disease and 21 (35%) had pneumonia. Several patients had fungal infections: 10 (17%) had an invasive candidal infection (six candidemia, one lung, one hepatosplenic candidiasis, one disseminated, one urinary tract infection), six (10%) had an invasive mold infection (four lung, one lung and brain, one sinus), and one had disseminated blastomycosis. Thirteen (22%) patients had CMV disease (10 viremia, one pneumonia, one disseminated and one encephalitis 19 non-tunneled catheters, and 15 implanted ports) and 31 (52%) had a urinary catheter. Mucositis was reported in 42 (70%) patients, of whom 11 had Xgrade 2 mucositis, with 19 (32%) receiving enteral feeding (17 nasogastric tube, two percutaneous tubes) and 20 (33%) total parenteral nutrition (TPN). As mentioned above, 13 patients had gastrointestinal GVHD (seven acute, six chronic) and six had C. difficile-associated disease. End-organ dysfunction was common: 20 (33%) patients had liver dysfunction (serum bilirubin 42.0 mg/dl), 19 (32%) had acute neurologic dysfunction (mental status changes or new focal deficit), 13 (22%) patients were mechanically ventilated, 11 (18%) patients had acute renal dysfunction (serum creatinine 42.0 mg/dl or doubling of baseline; two required acute dialysis) and six (10%) had gastrointestinal dysfunction (ileus or bleeding requiring transfusion). The mean APACHE II score 48 h before the VRE BSI was 17.4 and the mean APACHE II score at the time of the VRE BSI was 18.1 (P ¼ 0.23).
Treatment of VRE BSI
All enterococcal blood isolates at our institution were tested for sensitivity to vancomycin, ampicillin, gentamicin and streptomycin. All isolates except one (the E. faecalis isolate) were resistant to all antibiotics tested. The one isolate that was not pan-resistant was sensitive to ampicillin. Upon detection of the VRE BSIs, 33 (55%) patients underwent central venous catheter removal. Thirty (50%) patients were treated with linezolid (three also received ampicillin), 16 (27%) with chloramphenicol (two also received ampicillin), three (5%) with quinuprisitin/dalfopristin and one (o1%) patient was treated with high-dose ampicillin alone. In 25 (42%) patients, antibiotics with activity against VRE were started within 48 h from the time the culture was obtained. Ten patients did not receive any antibiotics with potential activity against VRE, all of whom had a single culture positive for VRE. Three died within 48 h from when the blood culture was drawn. Four of the seven who did not die within 48 h were treated with removal of their central venous catheters alone. All four survived 4210 days after the VRE BSI. Of the three who received no specific treatment, one was discharged on hospice and died 29 days after the VRE BSI from disease progression. The other two survived 4240 days after the VRE BSI. None of the seven developed recurrent VRE BSI.
Survival after VRE BSI Thirty-two (53%) patients died during the VRE BSI hospitalization and the median survival after VRE BSI was 19 days (Figure 2 ). Only four deaths were felt to be directly attributable to the VRE BSI by chart review. All four patients developed septic shock that coincided with the VRE BSI without other identifiable causes. Two of the patients had myelodysplastic syndrome, one had acute myelogenous leukemia and one had Hodgkin's disease. Three patients had an allogeneic transplant (one unrelated donor), all of whom had GVHD. Three of the patients were treated with chloramphenicol and one with linezolid. Time from VRE BSI to death ranged from 2 to 20 days.
Variables associated with death during the VRE BSI hospitalization on univariate analysis included age, hospitalization in the previous 30 days, ECOG score X2 on admission, transplant status, admission for GVHD, pneumonia, receipt of non-prophylactic anti-fungals or anti-anaerobic antibiotic, mechanical ventilation, acute neurologic dysfunction, TPN, APACHE II score at time of VRE BSI, VRE BSI treated with chloramphenicol and non-removal of the central venous catheter after VRE BSI (Table 2 ). There was a trend towards improved survival when linezolid was used to treat the VRE BSI. Factors not associated with death include underlying disease, CMV disease, invasive mold infection, neutropenia at time of VRE BSI, severe mucositis, change in APACHE II score Figure 2 Kaplan-Meier analysis of survival to discharge. Table 2 Risk factors for not surviving VRE BSI hospitalization on univariate analysis (n (%) or median (range)) from 48 h before VRE BSI to day of VRE BSI, 41 day of VRE bacteremia, initiation of treatment for VRE within 48 h of the VRE BSI and recurrent VRE BSI. Variables associated with death on multivariable Cox analysis included hospitalization for GVHD, pneumonia, receipt of non-prophylactic anti-fungals and APACHE II score at the time of the VRE BSI (Table 3) .
Discussion
In this study, we sought to describe HSCT recipients and patients with hematological malignancies who developed VRE BSI and determine risk factors for death over an 83-month-study period. We found that patients who developed VRE BSI were severely ill from complications related to the underlying disease and its treatment, and often had concomitant infections and frequent exposures to antimicrobial agents. Although 52% of patients with VRE BSI did not survive their hospitalization, only four deaths were felt to be directly attributable to the VRE BSI by chart review. Enterococcus is not an inherently virulent organism. 27 This may be why three patients survived without any specific therapy. These patients had only one culture positive indicating they had a transient bacteremia. By the time it was known VRE was the causative organism of the BSI the patients had not received appropriate antibiotics for several days. As repeat blood cultures did not grow VRE, the primary team did not feel it necessary to start therapy active against VRE. This is in line with our findings that VRE was not the direct cause of death in the majority of our patients that died after their VRE BSI. This observation raises an important question: did patients die from the VRE BSI or with the VRE BSI?
Recently DiazGranados and Jernigan 20 reported the impact of vancomycin resistance on clinical outcomes in 22 neutropenic patients who developed a VRE BSI and compared their outcomes to 61 neutropenic patients who developed vancomycin-senstivie enterococcal BSIs. Seventy-seven (93%) of the patients had an underlying hematologic malignancy. Mortality of patients with VRE BSI was 64% at 60 days after the onset of bacteremia. They found vancomycin resistance to be a risk factor for death owing to prolonged bacteremia (HR 4.9, CI 1.2-20.4). All patients with VRE BSI in their study were treated initially with chloramphenicol. In our study, 50% of patients received linezolid whereas only 27% were treated with chloramphenicol. On univariate analysis we found treatment of the VRE BSI with chloramphenicol to be associated with an increased risk of death. Of note, none of our patients treated with chloramphenicol experienced any marrow suppression owing to the chloramphenicol (data not shown).
Avery et al. 22 described the outcomes of 12 allogeneic transplant recipients who developed VRE BSI. Ten of 12 patients experienced VRE BSI during the neutropenic period (median 15 days post transplant, range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] , and mainly this occurred in patients with refractory or relapsed disease at the time of transplantation (70%). All VRE BSI patients were co-infected with other organisms including gram-negative bacilli, fungi or CMV, and five patients had intra-abdomial complications (GVHD, cholecystitis or typhlitis). Patients received linezolid (five), chloramphenicol (two) and quinuprisitin/dalfopristin (n ¼ 5). Patients died a median of 18 days after onset of VRE BSI (range 7-73), and only one death was directly attributable to VRE. Results of this study are comparable to our analysis with regards to the co-morbidities present at the time of onset of VRE BSI and the low rate of death directly attributable to VRE. However, in our study, VRE BSI was observed later after allografting with only 10/38 (26%) VRE BSI occurring within 21 days post transplant in allograft recipients.
There were several important findings of this study that have impacted how we manage our patients. Although treatment with linezolid and removal of the central venous catheter were not associated with improved survival on multivariable analysis, because they were associated with improved outcomes on univariate analysis they have become the standard of care for treating VRE BSI on our HSCT unit. VRE in the US is almost completely healthcare-associated and is transmitted primarily by the hands of health-care workers. Our data demonstrated a trend towards a decrease in the incidence of VRE BSI with more aggressive infection control measures. This trend continued beyond the study period with continued gown and glove use when caring for patients with VRE colonization (data not shown). This finding stresses the importance of preventing the spread of VRE, and wearing gowns and gloves when caring for patients colonized with VRE has remained the standard of care on out HSCT unit.
Our study suffers from the same limitations as other studies focused on patients with VRE BSI and studies to determine the attributable mortality owing to infections, [14] [15] [16] [17] [18] [19] [20] 28, 29 that is, lack of appropriate controls, limited heterogenous objective methods controlling for the complexity and the severity of underlying illness and impact of effective therapy over time. Our study does describe the largest cohort of HSCT recipients and patients with hematologic malignancies with VRE BSI in the literature to date. We believe that VRE BSI was not the direct cause of death in most patients who died. This is supported by our findings that factors previously associated with an increased risk of death owing to infections, timing of antibiotics and duration of bacteremia, were not associated with an increased risk of death in this study. In addition, the APACHE II score did not change significantly from 48 h before the VRE BSI to the time of the VRE BSI, indicating the VRE BSI was not associated with an acute clinical deterioration in the majority of patients. However, these patients were extremely ill at baseline and the additional insult of the VRE BSI could have contributed to death in ways too subtle for us to detect.
In conclusion, this study suggests that in HSCT recipients and patients with hematological malignancies VRE may not have the microbiological behavior of a virulent pathogen. VRE BSI may simply be a marker of disease severity in patients that are otherwise at high risk for death.
